Pharmacy Times

JANUARY 5, 2025

Fiber-rich foods show improvements in health and reductions in chronic diseases, including obesity, by promoting weight management and enhancing the metabolism.

89

89

The FDA Law Blog

JANUARY 5, 2025

By Deborah L. Livornese As promised in the Fall Unified Regulatory Agenda, FDA issued the final rule to establish the pathway to obtain marketing approval of a nonprescription drug product with an additional condition for nonprescription use (ACNU) on December 26, 2024, before the end of the calendar year. 89 Fed. Reg. 105288 (Dec. 26, 2024). We described the 2022 proposed rule and the ten-plus year history leading up to its issuance in our blog post here.

Labelling 59

Labelling FDA 59

Med Ed 101

JANUARY 5, 2025

I’ve had some wonderful guest posts in the past and I couldn’t help but notice this awesome post on LinkedIn from a fellow pharmacist! April Oliveros is the author of this quick hitter on “Does Every Patient On Anticoagulation Need a PPI?” You can connect and follow her on LinkedIn right here. As clinical pharmacists, […] The post Does Every Patient On Anticoagulation Need a PPI?

52

52

Pharmaceutical Technology

JANUARY 5, 2025

LR-19155 is under clinical development by LG Chem and currently in Phase I for Non-Small Cell Lung Cancer.

40

40

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

IDStewardship

JANUARY 5, 2025

In this article we do a quick run down on IDstewardship for the end of 2024. Article Posted January 2025 It was welcomed that 2024 did not feel like an extension of the 2020 COVID-19 pandemic as 2021-2023 had. I think many of us working in the infectious diseases space were grateful not to be at the mercy of pandemic demands. 2024 was a slower year for IDstewardship in regards to content creation and online engagement, but that still meant a lot of great new things were released.

Communication 130

Communication 130

Pharmaceutical Technology

JANUARY 5, 2025

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Cervical Cancer.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

HLC-001 is under clinical development by Human Life CORD Japan and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

NMDA Regulator is under clinical development by Boehringer Ingelheim International and currently in Phase I for Unspecified Central Nervous System Disorders.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

Paclitaxel is under clinical development by InnoUp Farma and currently in Phase I for Solid Tumor.

40

40

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmaceutical Technology

JANUARY 5, 2025

Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

Coronavirus Disease 2019 (COVID-19) vaccine is under clinical development by China National Biotec Group and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Vaccines 40

Vaccines 40

Pharmaceutical Technology

JANUARY 5, 2025

BNT-325 is under clinical development by BioNTech and currently in Phase II for Malignant Mesothelioma.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

RG-6315 is under clinical development by Genentech USA and currently in Phase I for Systemic Sclerosis (Scleroderma).

40

40

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmaceutical Technology

JANUARY 5, 2025

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.

Immunization 40

Immunization 40

Pharmaceutical Technology

JANUARY 5, 2025

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Relapsed Acute Myeloid Leukemia.

Immunization 40

Immunization 40

Pharmaceutical Technology

JANUARY 5, 2025

AKS-452 is under clinical development by Vakston and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

40

40

Pharmaceutical Technology

JANUARY 5, 2025

SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Pancreatic Cancer.

40

40

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmaceutical Technology

JANUARY 5, 2025

(Ensifentrine + glycopyrrolate) is under clinical development by Verona Pharma and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD).

40

40

Pharmaceutical Technology

JANUARY 5, 2025

LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Ovarian Cancer.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).

40

40

Pharmaceutical Technology

JANUARY 5, 2025

GM-103 is under clinical development by Genemedicine and currently in Phase II for Metastatic Colorectal Cancer.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

SB-207 is under clinical development by Pelthos Therapeutics and currently in Phase II for Genital Warts (Condylomata Acuminata).

40

40

Pharmaceutical Technology

JANUARY 5, 2025

RG-6315 is under clinical development by Genentech USA and currently in Phase I for Systemic Sclerosis (Scleroderma).

40

40

Pharmaceutical Technology

JANUARY 5, 2025

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.

Immunization 40

Immunization 40

Pharmaceutical Technology

JANUARY 5, 2025

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Relapsed Acute Myeloid Leukemia.

Immunization 40

Immunization 40

Pharmaceutical Technology

JANUARY 5, 2025

AKS-452 is under clinical development by Vakston and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

40

40

Pharmaceutical Technology

JANUARY 5, 2025

SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Pancreatic Cancer.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

(Ensifentrine + glycopyrrolate) is under clinical development by Verona Pharma and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD).

40

40

Pharmaceutical Technology

JANUARY 5, 2025

LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Ovarian Cancer.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).

40

40

Pharmaceutical Technology

JANUARY 5, 2025

GM-103 is under clinical development by Genemedicine and currently in Phase II for Metastatic Colorectal Cancer.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

SB-207 is under clinical development by Pelthos Therapeutics and currently in Phase II for Genital Warts (Condylomata Acuminata).

40

40